Sherry Kallingal
Senior Director - Operational Excellence ProKidney
Sherry Kallingal is Senior Director of Operational Excellence at ProKidney, leading Supply Chain and Manufacturing Operations Excellence for autologous cell therapy. With over 25 years driving digital transformation in GMP-regulated pharmaceutical and biotechnology environments, his expertise spans leading and implementing Chain of Identity/Chain of Custody platforms, ERP/MES/Labeling, and integrated digital ecosystems for personalized manufacturing. He specializes in assessing digital maturity, establishing data governance, and phasing scalable platform adoption to align with organizational capabilities, delivering immediate operational benefit while building foundations for future innovation. Sherry has partnered with global pharmaceutical organizations, CDMOs (Catalent, Aptuit), and emerging biotech’s (CRISPR Therapeutics, ProKidney) to transform fragmented systems into data-enabled operations.
Seminars
It has long been recognised that cell and gene therapy must embrace digitalization, but the question remains: how do we get there? As AI adoption accelerates across the industry, establishing the right digital foundations is critical to enabling this transformation. Whilst there is broad agreement on the need for this transition, organizations face constraints around time, cost, and resources. Attendees will learn how to digitalize effectively, manage costs, and embed digitalization into a sustainable business plan.
This workshop will explore:
- Preparing for AI Adoption: laying the digital groundwork by assessing current digital maturity, implementing robust data governance, and identifying areas where AI can deliver immediate operational benefit
- Industrializing Personalized Manufacturing: using digital platforms to accelerate patient-to-product journeys through improved chain of identity, logistics integration, and real-time operational visibility
- Optimizing Cost and Time: reducing implementation timelines and controlling costs by prioritizing high-impact digital initiatives, leveraging scalable platforms, and avoid redundant digitalization efforts
- Digitalizing Emerging Biotechs: learn from industry leaders how to leverage industry-standard platforms, demonstrating the phased adoption of digital tools, and aligning digital investment with organizational maturity
